DD282396A5 - Verfahren zur herstellung von rezepturen zur transmukosalen aufnahme - Google Patents

Verfahren zur herstellung von rezepturen zur transmukosalen aufnahme Download PDF

Info

Publication number: DD282396A5
Authority: DD; German Democratic Republic
Prior art keywords: preparation; insulin; cyclodextrin; monosaccharide; group
Prior art date: 1987-09-14

Application number

DD31974488A

Other languages

German (de)

English (en)

Inventor

Anders R Sorensen

Anne Engesgaard

Philip E Hansen

Original Assignee

Novo Industri A/S,Dk

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-09-14

Filing date

1988-09-13

Publication date

1990-09-12

1988-09-13 Application filed by Novo Industri A/S,Dk filed Critical Novo Industri A/S,Dk

1990-09-12 Publication of DD282396A5 publication Critical patent/DD282396A5/de

Links

238000004519 manufacturing process Methods 0.000 title description 2
238000002360 preparation method Methods 0.000 claims abstract description 54
238000000034 method Methods 0.000 claims abstract description 25
229920000858 Cyclodextrin Polymers 0.000 claims abstract description 18
239000000203 mixture Substances 0.000 claims abstract description 17
150000002772 monosaccharides Chemical class 0.000 claims abstract description 15
150000001720 carbohydrates Chemical group 0.000 claims abstract description 13
229920001184 polypeptide Polymers 0.000 claims abstract description 13
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 13
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 13
239000000126 substance Substances 0.000 claims abstract description 11
239000013543 active substance Substances 0.000 claims abstract description 10
239000007788 liquid Substances 0.000 claims abstract description 9
229920001542 oligosaccharide Polymers 0.000 claims abstract description 8
150000002482 oligosaccharides Chemical class 0.000 claims abstract description 8
239000003795 chemical substances by application Substances 0.000 claims abstract description 7
239000003755 preservative agent Substances 0.000 claims abstract description 7
230000002335 preservative effect Effects 0.000 claims abstract description 7
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims abstract description 4
239000002207 metabolite Chemical group 0.000 claims abstract description 4
230000003204 osmotic effect Effects 0.000 claims abstract description 4
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 3
230000001105 regulatory effect Effects 0.000 claims abstract description 3
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 3
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 58
102000004877 Insulin Human genes 0.000 claims description 27
108090001061 Insulin Proteins 0.000 claims description 27
229940125396 insulin Drugs 0.000 claims description 26
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 15
PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 11
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 9
239000003085 diluting agent Substances 0.000 claims description 9
HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 7
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 5
239000001116 FEMA 4028 Substances 0.000 claims description 5
102000051325 Glucagon Human genes 0.000 claims description 5
108060003199 Glucagon Proteins 0.000 claims description 5
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 5
235000011175 beta-cyclodextrine Nutrition 0.000 claims description 5
229960004853 betadex Drugs 0.000 claims description 5
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical group C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 5
229960004666 glucagon Drugs 0.000 claims description 5
SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 4
GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 4
229940080345 gamma-cyclodextrin Drugs 0.000 claims description 4
229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 3
SRBFZHDQGSBBOR-SOOFDHNKSA-N D-ribopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@@H]1O SRBFZHDQGSBBOR-SOOFDHNKSA-N 0.000 claims description 3
LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 claims description 3
SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 claims description 3
239000004026 insulin derivative Substances 0.000 claims description 3
YTBSYETUWUMLBZ-UHFFFAOYSA-N D-Erythrose Natural products OCC(O)C(O)C=O YTBSYETUWUMLBZ-UHFFFAOYSA-N 0.000 claims description 2
ZAQJHHRNXZUBTE-NQXXGFSBSA-N D-ribulose Chemical compound OC[C@@H](O)[C@@H](O)C(=O)CO ZAQJHHRNXZUBTE-NQXXGFSBSA-N 0.000 claims description 2
ZAQJHHRNXZUBTE-UHFFFAOYSA-N D-threo-2-Pentulose Natural products OCC(O)C(O)C(=O)CO ZAQJHHRNXZUBTE-UHFFFAOYSA-N 0.000 claims description 2
HSNZZMHEPUFJNZ-UHFFFAOYSA-N L-galacto-2-Heptulose Natural products OCC(O)C(O)C(O)C(O)C(=O)CO HSNZZMHEPUFJNZ-UHFFFAOYSA-N 0.000 claims description 2
HAIWUXASLYEWLM-BNWJMWRWSA-N beta-D-sedoheptulopyranose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@H](O)[C@@H]1O HAIWUXASLYEWLM-BNWJMWRWSA-N 0.000 claims description 2
150000002386 heptoses Chemical class 0.000 claims description 2
150000002402 hexoses Chemical class 0.000 claims description 2
150000002972 pentoses Chemical class 0.000 claims description 2
150000003538 tetroses Chemical class 0.000 claims description 2
229940043377 alpha-cyclodextrin Drugs 0.000 claims 2
125000000139 D-erythrosyl group Chemical group C1([C@H](O)[C@H](O)CO1)* 0.000 claims 1
125000000137 D-lyxosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)CO1)* 0.000 claims 1
239000006179 pH buffering agent Substances 0.000 claims 1
229940079593 drug Drugs 0.000 abstract description 18
239000003814 drug Substances 0.000 abstract description 18
238000010521 absorption reaction Methods 0.000 abstract description 8
239000004480 active ingredient Substances 0.000 abstract description 6
238000009472 formulation Methods 0.000 abstract description 6
239000006172 buffering agent Substances 0.000 abstract description 4
239000007884 disintegrant Substances 0.000 abstract 1
230000009885 systemic effect Effects 0.000 abstract 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
239000000243 solution Substances 0.000 description 10
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
101000976075 Homo sapiens Insulin Proteins 0.000 description 8
239000008280 blood Substances 0.000 description 8
210000004369 blood Anatomy 0.000 description 8
239000008103 glucose Substances 0.000 description 8
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 8
241000283973 Oryctolagus cuniculus Species 0.000 description 7
238000012360 testing method Methods 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
239000000843 powder Substances 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
230000037406 food intake Effects 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
239000004570 mortar (masonry) Substances 0.000 description 4
210000001331 nose Anatomy 0.000 description 4
-1 polyoxyethylene Polymers 0.000 description 4
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
239000000725 suspension Substances 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
108091005804 Peptidases Proteins 0.000 description 3
102000035195 Peptidases Human genes 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000002775 capsule Substances 0.000 description 3
230000002708 enhancing effect Effects 0.000 description 3
238000004108 freeze drying Methods 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
239000003380 propellant Substances 0.000 description 3
239000012744 reinforcing agent Substances 0.000 description 3
239000007921 spray Substances 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
MLKLDGSYMHFAOC-AREMUKBSSA-N 1,2-dicapryl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCC MLKLDGSYMHFAOC-AREMUKBSSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
239000004365 Protease Substances 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
229940097362 cyclodextrins Drugs 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
239000010685 fatty oil Substances 0.000 description 2
239000007789 gas Substances 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
230000010224 hepatic metabolism Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
210000003928 nasal cavity Anatomy 0.000 description 2
MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
235000021317 phosphate Nutrition 0.000 description 2
229920000056 polyoxyethylene ether Polymers 0.000 description 2
229960003712 propranolol Drugs 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000011701 zinc Substances 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
101001011741 Bos taurus Insulin Proteins 0.000 description 1
102000055006 Calcitonin Human genes 0.000 description 1
108060001064 Calcitonin Proteins 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102100023804 Coagulation factor VII Human genes 0.000 description 1
239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 1
108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 1
KTVPXOYAKDPRHY-MBMOQRBOSA-N D-Ribose 5-phosphate Natural products O[C@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O KTVPXOYAKDPRHY-MBMOQRBOSA-N 0.000 description 1
YTBSYETUWUMLBZ-IUYQGCFVSA-N D-erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108010023321 Factor VII Proteins 0.000 description 1
108010054218 Factor VIII Proteins 0.000 description 1
102000001690 Factor VIII Human genes 0.000 description 1
108700012941 GNRH1 Proteins 0.000 description 1
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
239000005909 Kieselgur Substances 0.000 description 1
102000009151 Luteinizing Hormone Human genes 0.000 description 1
108010073521 Luteinizing Hormone Proteins 0.000 description 1
206010028741 Nasal inflammation Diseases 0.000 description 1
102000003982 Parathyroid hormone Human genes 0.000 description 1
108090000445 Parathyroid hormone Proteins 0.000 description 1
241001319148 Pharmacis Species 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
108010005991 Pork Regular Insulin Proteins 0.000 description 1
108010076181 Proinsulin Proteins 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
108090000783 Renin Proteins 0.000 description 1
102100028255 Renin Human genes 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
102100022831 Somatoliberin Human genes 0.000 description 1
101710142969 Somatoliberin Proteins 0.000 description 1
102000005157 Somatostatin Human genes 0.000 description 1
108010056088 Somatostatin Proteins 0.000 description 1
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
102000011923 Thyrotropin Human genes 0.000 description 1
108010061174 Thyrotropin Proteins 0.000 description 1
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
108010004977 Vasopressins Proteins 0.000 description 1
102000002852 Vasopressins Human genes 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
PPQRONHOSHZGFQ-LMVFSUKVSA-N aldehydo-D-ribose 5-phosphate Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PPQRONHOSHZGFQ-LMVFSUKVSA-N 0.000 description 1
229930013930 alkaloid Natural products 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
108010082685 antiarrhythmic peptide Proteins 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
229940093761 bile salts Drugs 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
238000004820 blood count Methods 0.000 description 1
IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
229960004015 calcitonin Drugs 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
125000004181 carboxyalkyl group Chemical group 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
229920003086 cellulose ether Polymers 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
229940015047 chorionic gonadotropin Drugs 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
229930003836 cresol Natural products 0.000 description 1
PWZFXELTLAQOKC-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide;tetrahydrate Chemical compound O.O.O.O.[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O PWZFXELTLAQOKC-UHFFFAOYSA-A 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229940012413 factor vii Drugs 0.000 description 1
229960000301 factor viii Drugs 0.000 description 1
230000003325 follicular Effects 0.000 description 1
108010074605 gamma-Globulins Proteins 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
150000004668 long chain fatty acids Chemical class 0.000 description 1
229940040129 luteinizing hormone Drugs 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000035800 maturation Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
210000002850 nasal mucosa Anatomy 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000001272 nitrous oxide Substances 0.000 description 1
229920000620 organic polymer Polymers 0.000 description 1
239000000199 parathyroid hormone Substances 0.000 description 1
229960001319 parathyroid hormone Drugs 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
150000008105 phosphatidylcholines Chemical class 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229940051841 polyoxyethylene ether Drugs 0.000 description 1
239000003761 preservation solution Substances 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
238000005086 pumping Methods 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000012439 solid excipient Substances 0.000 description 1
229960000553 somatostatin Drugs 0.000 description 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000005495 thyroid hormone Substances 0.000 description 1
229940036555 thyroid hormone Drugs 0.000 description 1
229960000874 thyrotropin Drugs 0.000 description 1
230000001748 thyrotropin Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
229960000187 tissue plasminogen activator Drugs 0.000 description 1
239000012745 toughening agent Substances 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
229960003726 vasopressin Drugs 0.000 description 1
WHGYBXFWUBPSRW-FEYSZYNQSA-N β-dextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)C(O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FEYSZYNQSA-N 0.000 description 1

Landscapes

Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

DD31974488A 1987-09-14 1988-09-13 Verfahren zur herstellung von rezepturen zur transmukosalen aufnahme DD282396A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DK477487A DK477487D0 (da)	1987-09-14	1987-09-14	Praeparat

Publications (1)

Publication Number	Publication Date
DD282396A5 true DD282396A5 (de)	1990-09-12

Family

ID=8136541

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD31974488A DD282396A5 (de)	1987-09-14	1988-09-13	Verfahren zur herstellung von rezepturen zur transmukosalen aufnahme

Country Status (3)

Country	Link
DD (1)	DD282396A5 (da)
DK (1)	DK477487D0 (da)
ZA (1)	ZA886775B (da)

1987
- 1987-09-14 DK DK477487A patent/DK477487D0/da not_active Application Discontinuation
1988
- 1988-09-12 ZA ZA886775A patent/ZA886775B/xx unknown
- 1988-09-13 DD DD31974488A patent/DD282396A5/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
ZA886775B (en)	1989-05-30
DK477487D0 (da)	1987-09-14

Legal Events

Date	Code	Title	Description
1995-06-08	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
DE69532884T2 (de)	2004-09-02	Verfahren und mittel zur verabreichung von insulin über die lunge
DE3875025T2 (de)	1993-06-24	Calcitonin enthaltende zusammensetzung fuer die nasale verabreichung.
DE69821872T2 (de)	2005-01-05	Teriparatidhaltige stabilisierte Lösungen
EP0308181A1 (en)	1989-03-22	Trans-mucosal delivery formulations and a method for preparation thereof
DE3780925T2 (de)	1992-12-24	Nasale formulierungen und verfahren zu deren herstellung.
DE69813322T2 (de)	2004-02-19	Flüssige gonadotropinhaltige Arzneimittel
DE68918853T2 (de)	1995-04-13	Formulierung von menschlichen wachstumshormonen.
DE69832631T2 (de)	2006-08-10	Zusammensetzungen geeignet zur kontrollierten freisetzung des hormons gnrh und dessen analoga
DE69435033T2 (de)	2008-05-29	Parathormonarzneizusammensetzung
DE69102465T2 (de)	1995-03-02	Stabilisierte Gonadotropin enthaltende Zubereitungen.
CH683749A5 (de)	1994-05-13	Pharmazeutische Nasalzusammensetzung.
DE4242863A1 (de)	1994-06-23	Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
CN101151048A (zh)	2008-03-26	增强甲状旁腺激素粘膜递送的组合物和方法
DE69230672T2 (de)	2000-09-21	Gonadotropin, das pharmazeutische zusammensetzungen mit sucrose stabilisator enthält
EP0876140A2 (de)	1998-11-11	Verbesserte konzentrierte injektions- und infusionslösungen für die intravasale anwendung
EP1282400B1 (de)	2016-12-14	Pharmazeutische darreichungsform für peptide, verfahren zu deren herstellung und verwendung
DE69420872T2 (de)	2000-01-13	Hgh enthaltende pharmazeutische zubereitungen
DE69819322T2 (de)	2004-07-29	Pharmazeutische zubereitung enthaltend peptide mit geringer löslichkeit in physiologischem medium
DE60009926T2 (de)	2005-04-07	Stabilisierung von gefriergetrocknetem kuchen
JPH05509101A (ja)	1993-12-16	経粘膜薬物製剤および経粘膜投与法
BE1006873A6 (nl)	1995-01-10	Toedieningsformulering voor nasale insuline toediening.
DE69231263T2 (de)	2000-12-21	Calcitonin enthaltende pharmazeutische Zusammensetzungen
DE60020939T2 (de)	2006-05-11	Salze von pharmakologisch aktiven peptiden mit verzögerter wirkstofffreigabe und deren herstellung
Richardson et al.	1989	Vaginal administration of gentamicin to rats. Pharmaceutical and morphological studies using absorption enhancers
DE1518057C3 (de)	1974-04-18	Injizierbares adrenocorticotropes Hormonpräparat mit prolongierter ACTH-Aktivität